Beigene, Ltd.

Beijing Hanmi Pharmaceutical Co., Ltd.

Chinese Academy of Medical Sciences

Beigene Switzerland Gmbh

Hai Xue

Tao Ma

Zhiwei Wang

Lin Wang

Gang Liu

Yunhang Guo

Hanzi Sun

Maengsup Kim

Tao Zhao

Mi Young Cha

Ziwei Chen

Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.

Bcl-2 inhibitor

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

BCL-2 inhibitors

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same. 

Bcl-2 inhibitors

Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a ROR&#x3b3; mediated disease. The compound has the structural formula (I). 

N-benzoate group substituted benzopyrroline-2-one derivative and use thereof

Growing community of inventors

Beijing, China

Hai Xue